TERT promoter mutation is associated with worse prognosis in melanoma, glioma, meningioma, thyroid cancer, and bladder cancer [12–18] and is also associated with a high risk of malignant transformation and progression to advanced stages in hepatocellular carcinoma [19, 20]. Here, TERT is linked to melanoma.